Zhong Guo Jing Ji Wang·2025-10-09 02:56Core Viewpoint - Shouyao Holdings (688197.SH) reported a significant decline in revenue and continued net losses for the first half of 2025, indicating ongoing financial challenges for the company [1]. Financial Performance - The company achieved a revenue of 2 million yuan in the first half of 2025, representing a year-on-year decrease of 47.37% from 3.8 million yuan in the same period last year [3]. - The net profit attributable to shareholders was -104.37 million yuan, slightly worsening from -102.85 million yuan in the previous year [3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -114.25 million yuan, compared to -109.89 million yuan in the same period last year [3]. - The net cash flow from operating activities was -113.62 million yuan, compared to -97.14 million yuan in the same period last year [3]. Company Background - Shouyao Holdings was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 23, 2022, with an initial offering price of 39.90 yuan per share [4]. - The total amount raised during the IPO was 1.483 billion yuan, with a net amount of 1.374 billion yuan after deducting issuance costs [4]. - The company intended to use the raised funds for innovative drug research and development projects, establishing a new drug R&D and industrialization base, and supplementing working capital [4].